The Swiss pharmaceutical association Interpharma said this means that access to vital medicines is becoming increasingly difficult.
The benchmarking study conducted by the pharmaceutical industry and the Swiss Agency for Therapeutic Products, Swissmedic, reveals that companies are submitting their applications later in Switzerland compared to Europe, and that the duration of the review process has also increased, Interpharma announced on Wednesday.
More
More
What’s behind Switzerland’s push for drug-pricing secrecy?
This content was published on
The Swiss parliament is considering measures on drug pricing that are drawing the ire of some health experts.
On average, a drug is approved in Switzerland 249 days later than by the EMA, which represents a 48% increase compared to the previous year. Companies submitted their applications for authorisation to Swissmedic 244 days later than to the EMA.
Interpharma attributes this to the poor framework conditions in Switzerland, which have caused the Swiss market to receive progressively less priority.
Translated from German by DeepL/sp
This news story has been written and carefully fact-checked by an external editorial team. At SWI swissinfo.ch we select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate it into English. Providing you with automatically translated news gives us the time to write more in-depth articles.
If you want to know more about how we work, have a look here, if you want to learn more about how we use technology, click here, and if you have feedback on this news story please write to english@swissinfo.ch.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
Popular Stories
More
Culture
Wealth is not all: how gentrification in Zurich has led to housing shortage
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
Switzerland increasingly a target for people smuggling and trafficking
This content was published on
Switzerland is increasingly being targeted by organized crime. This also applies to commercial people smuggling, the fastest growing criminal market in Europe.
Swiss forests better equipped against storms 25 years after Lothar
This content was published on
Twenty-five years ago, Hurricane Lothar toppled trees like dominoes in Switzerland. Forests today are better prepared to cope with such an exceptional event, say experts.
This content was published on
The Locarno Film Festival is considering moving from the beginning of August to the second half of July for its 80th edition in 2027.
Council of Europe head Alain Berset visits Georgia
This content was published on
The Secretary General of the Council of Europe, Alain Berset, is visiting Georgia, which has been rocked by a political crisis, from Wednesday.
Swiss politician who shot at Jesus faces criminal proceedings
This content was published on
The Zurich public prosecutor's office has opened criminal proceedings against politician Sanija Ameti. It is investigating whether she disrupted freedom of religion and worship.
Switzerland must be able to control immigration, says head of business federation
This content was published on
Switzerland must be able to control immigration itself if it "exceeds the tolerable limits", says Christoph Mäder, president of Economiesuisse, the Swiss Business Federation.
This content was published on
The film Reinas by Klaudia Reynicke, a Swiss-Peruvian-Spanish co-production, has missed out on an Oscar nomination for Best Foreign Film.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Secret discounts leave patients at drugmakers’ mercy
This content was published on
A University of Zurich study has found that using confidential discounts on drugs does little to make them available faster and more affordable.
How drug prices are negotiated in Switzerland and beyond
This content was published on
Switzerland's pharmaceutical sector supplies drugs worldwide, but not all countries receive them with the same price tag. Here's why.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.